Surgery plus drugs may extend life in advanced liver cancer

NCT ID NCT07537959

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether surgically removing the main liver tumor, followed by standard immune-based drug therapy, can help people with liver cancer that has spread to other organs live longer. About 280 adults with resectable liver tumors and at least one metastasis will be randomly assigned to surgery plus drugs or drugs alone. The main goal is overall survival, with secondary measures including cancer progression and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
primary tumor resection (surgery) plus immune-based systemic therapy
What this could lead to
If successful, this could show that combining surgery with standard drug therapy extends life for people with liver cancer that has spread.
What could go wrong
This is an early-stage trial with no results yet. Surgery carries risks like infection or bleeding, and the added benefit over drugs alone is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.